{
  "docId": "019dd923-622c-750b-8b9a-1a3bea94baf9",
  "docSlug": "c358888161f0",
  "documentTitle": "Ginkgo Bioworks (DNA)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-10-06 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 169,
  "pageCount": 175,
  "prevPage": 168,
  "nextPage": 170,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a 'villain/contradiction' framing to undermine the credibility of a key customer relationship.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-1a3bea94baf9/169",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-1a3bea94baf9",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-1a3bea94baf9.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-1a3bea94baf9#slide-169",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "A current Joyn executive called them “a glorified CRO” and said that while of their R&D spend is with Ginkgo today, by virtue of it being a captive entity, they’d slash that to 15-20% of their R&D budget if it was up to them.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-2b63-72e1-b602-27a6cecb8724",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "An ex-executive involved in setting up the venture called it “a moonshot” with “pretty small” chances, suggesting he’s heard nothing indicating success. An ex-strain engineer stated “there is not a lot of success coming out of that.” A current Joyn executive called them “a glorified CRO” and said that while of their R&D spend is with Ginkgo today, by virtue of it being a captive entity, they’d slash that to 15-20% of their R&D budget if it was up to them.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07d0114b-29c6-4606-9eca-0de342d869fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "quote",
      "text": "Senior Joyn employee would only spend 15-20% with Ginkgo if given the freedom to choose other vendors... “The percentage of our budget that goes to them today is probably 60%, 70%, or more right now... how we are working with them now is as a kind of a glorified CRO.” - Senior employee at Joyn",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c665d5a-bb91-4297-85f5-2ee15fb32fe0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "quote",
      "text": "Former strain engineer suggested Joyn is a failed project... “there is not a lot of success coming out of that... they haven't announced anything that was a big wow moment.” - Former Ginkgo strain engineer",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e4145c0-5681-435a-aaca-f097c44712ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "quote",
      "text": "Executive involved in setting it up hasn't heard of any progress, changes of success are “pretty small”... “I haven't heard anything... what are their chances? I think it's pretty small.” - Former Ginkgo executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b33154bb-6943-4d9d-a552-71df813cd39d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“I haven't heard anything. Honestly, I just know that they keep saying they're making progress, but they don't say what that progress is. I monitor it as well. Nothing's been announced. Nitrogen fixation is extremely difficult. It truly is a moonshot. If they get this to work, it's huge. But what are their chances? I think it's pretty small.” — Former Ginkgo executive; “The high throughput sequencing, the DNA synthesis, all of the highly automated processing of samples that they are really good at—all of that stuff is fine. I'd probably leave it at the 15% to 20% level. The percentage of our budget that goes to them today is probably 60%, 70%, or more right now. I don't actually have visibility on the whole R&D budget, unfortunately... how we are working with them now is as a kind of a glorified CRO.” — Senior employee at Joyn; “Joyn, it's hard to tell how far they've gotten. I know that testing things in the soil with plants takes a long time, but it seems like there is not a lot of success coming out of that...They are testing a strain in the field, from what I understand. But no, they've spent a long time working on it, and they haven't announced anything that was a big wow moment.” — Former Ginkgo strain engineer",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-2b63-72e1-b602-2b673b0eaed7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27cf2534-17ac-4603-926d-ddc001560516",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Case study 3: Joyn Bio, is a key related-party “customer” with Bayer involved in the venture, which is attempting to develop a nitrogen-fixing organism that can replace conventional nitrogen fertilizers.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5d184dd-207a-42d2-912a-83fc0f31cc0a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "expose_contradiction",
      "slug": null,
      "matchId": "190190a6-c392-4e37-a7d8-1efd408eb540",
      "evidence": "Contrasts official narrative of success with internal expert testimonials.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 175,
      "from": 9,
      "beatId": "ffe290af-3a4f-4e06-8d60-dfbfc07d2e08",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Expose Contradiction",
      "beatSlug": null,
      "evidence": "The deck presents evidence contradicting Ginkgo's claims and highlighting potential wrongdoings.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}